L Czirják1, C G Kiss, C Lövei, G Süto, C Varjú, Z Füzesi, T Illés, Z Nagy. 1. Department of Immunology and Rheumatology, Medical School, Hungarian Brothers of St. John of God and University of Pécs, Hungary. laszlo.czirjak@aok.pte.hu
Abstract
OBJECTIVES: To assess the prevalence of Raynaud's phenomenon (RP) and of RP associated systemic sclerosis (SSc) in a large regional representative study. METHODS: Ten thousand individuals aged between 14-65 years participated in face-to-face interviews. The stratified sample of the South-West Hungarian population was representative for age, sex and urban or rural residence. Individuals reporting complaints suggesting the presence of "clinically significant" RP were asked to undergo a clinical investigation. Patients showing complaints provoked by taking something out of the freezer (-20 degrees C) compartment of the refrigerator and/or whether they had experienced digital ulcers were sorted into this category. RESULTS: The overall prevalence of RP was at least 578.9/10,000, and the prevalence of "clinically significant" RP could be calculated as at least 87.7/10,000 inhabitants. In this latter group 17.2% of the cases had either established SSc or anticentromere antibody or scleroderma capillary pattern on nailfold capillaroscopy. SSc with "clinically significant" RP and/or ulcers was identified in a prevalence of 9.1/10.000 individuals, whilst there was a prevalence of 14.7/10,000 of RP with either anticentromere antibody or scleroderma capillary pattern. CONCLUSIONS: "Clinically significant" RP affects almost 1% of the population. We identified cases with early stages of scleroderma spectrum disorder showing either anticentromere autoantibody or scleroderma capillary pattern. The prevalence of SSc was found to be higher than expected. It is reasonable to screen "clinically significant" RP cases for scleroderma-related symptoms because this approach makes it possible to identify patients with both SSc and early scleroderma related symptoms.
OBJECTIVES: To assess the prevalence of Raynaud's phenomenon (RP) and of RP associated systemic sclerosis (SSc) in a large regional representative study. METHODS: Ten thousand individuals aged between 14-65 years participated in face-to-face interviews. The stratified sample of the South-West Hungarian population was representative for age, sex and urban or rural residence. Individuals reporting complaints suggesting the presence of "clinically significant" RP were asked to undergo a clinical investigation. Patients showing complaints provoked by taking something out of the freezer (-20 degrees C) compartment of the refrigerator and/or whether they had experienced digital ulcers were sorted into this category. RESULTS: The overall prevalence of RP was at least 578.9/10,000, and the prevalence of "clinically significant" RP could be calculated as at least 87.7/10,000 inhabitants. In this latter group 17.2% of the cases had either established SSc or anticentromere antibody or scleroderma capillary pattern on nailfold capillaroscopy. SSc with "clinically significant" RP and/or ulcers was identified in a prevalence of 9.1/10.000 individuals, whilst there was a prevalence of 14.7/10,000 of RP with either anticentromere antibody or scleroderma capillary pattern. CONCLUSIONS: "Clinically significant" RP affects almost 1% of the population. We identified cases with early stages of scleroderma spectrum disorder showing either anticentromere autoantibody or scleroderma capillary pattern. The prevalence of SSc was found to be higher than expected. It is reasonable to screen "clinically significant" RP cases for scleroderma-related symptoms because this approach makes it possible to identify patients with both SSc and early scleroderma related symptoms.
Authors: O Sander; C Sunderkötter; I Kötter; I Wagner; M Becker; I Herrgott; A Schwarting; B Ostendorf; C Iking-Konert; E Genth Journal: Z Rheumatol Date: 2010-05 Impact factor: 1.372
Authors: U A Walker; A Tyndall; L Czirják; C Denton; D Farge-Bancel; O Kowal-Bielecka; U Müller-Ladner; C Bocelli-Tyndall; M Matucci-Cerinic Journal: Ann Rheum Dis Date: 2007-01-18 Impact factor: 19.103
Authors: Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Panos Kanavos; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; Márta Péntek; Claudia Delgado; Johann Mathias von der Schulenburg; Ulf Persson; Karine Chevreul; Giovanni Fattore Journal: Eur J Health Econ Date: 2016-04-02
Authors: Yannick Allanore; Mohamad Saad; Philippe Dieudé; Jérôme Avouac; Jorg H W Distler; Philippe Amouyel; Marco Matucci-Cerinic; Gabriella Riemekasten; Paolo Airo; Inga Melchers; Eric Hachulla; Daniele Cusi; H-Erich Wichmann; Julien Wipff; Jean-Charles Lambert; Nicolas Hunzelmann; Kiet Tiev; Paola Caramaschi; Elisabeth Diot; Otylia Kowal-Bielecka; Gabriele Valentini; Luc Mouthon; László Czirják; Nemanja Damjanov; Erika Salvi; Costanza Conti; Martina Müller; Ulf Müller-Ladner; Valeria Riccieri; Barbara Ruiz; Jean-Luc Cracowski; Luc Letenneur; Anne Marie Dupuy; Oliver Meyer; André Kahan; Arnold Munnich; Catherine Boileau; Maria Martinez Journal: PLoS Genet Date: 2011-07-07 Impact factor: 5.917